Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,180 across all filing types
Latest filing 2023-10-06 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Intimation of Loss of share Certificates by Shareholder.
Regulatory Filings Classification · 90% confidence The document text is very short (1294 characters) and contains only digital signature information without any substantive content related to financial results, management changes, or other report types. There is no mention of any report, meeting, or announcement content. Given the lack of any report or announcement content and the presence of digital signatures only, this document most likely represents a Regulatory Filing (RNS) as a fallback category for miscellaneous filings that do not fit other categories.
2023-10-06 English
Loss of Share Certificates
Regulatory Filings Classification · 95% confidence The document text is extremely short (1066 characters) and contains only digital signature information without any substantive content related to financial performance, management changes, voting results, or other report details. There is no mention of any report title, fiscal period, or financial data. The content appears to be a certification or attestation by an individual rather than a full report or announcement. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2023-10-06 English
Lupin Receives Tentative Approval from U.S. FDA for Tolvaptan Tablets.
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative U.S. FDA approval for a generic drug application. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and product launch plans, not a financial report or detailed filing. The document length is 4196 characters, relatively short, and it does not contain financial statements or detailed analysis. It is not an earnings release, annual report, or interim report. It is a regulatory disclosure announcement about a business development event. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other categories.
2023-10-05 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing Lupin Limited's receipt of tentative U.S. FDA approval for a generic drug application. It is addressed to stock exchanges as a disclosure pursuant to SEBI Listing Regulations. The content is a corporate announcement about regulatory approval and product launch plans, not a financial report or detailed filing. The document length is 4185 characters, relatively short, and it does not contain financial statements or detailed analysis. It is not an earnings release, annual report, or management discussion. It is a regulatory disclosure announcement about a business development event. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and disclosures that do not fit other categories.
2023-10-05 English
Lupin Launches Humrahi, Unique Patient Support Program for Diabetes Management.
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new patient support program called 'Humrahi' by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Regulations, which typically covers material events or information about the company. The content focuses on the program details and company background, without any financial statements, management discussion, or regulatory filings. The document length is about 5,493 characters, which is relatively short and consistent with a press release or announcement rather than a detailed report. There is no indication of it being an annual report, earnings release, or any other detailed financial or governance document. Therefore, this fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure that does not fit other specific categories.
2023-10-03 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the launch of a new patient support program called 'Humrahi' by Lupin Limited. It is addressed to stock exchanges as a disclosure pursuant to Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which typically covers material events or information about the company. The content focuses on the program launch and company background, without any financial data, detailed financial performance, or regulatory filings. The document is about a corporate announcement rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-10-03 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.